cropped-bull-and-bear-logo

Newsmax IPO: A Stunning Rise and Fall in Stock Performance Explained

Newsmax IPO: A Historic Surge Followed by a Dramatic Decline Explosive Market Debut The recent Initial Public Offering (IPO) of Newsmax, a right-wing cable television network, captured headlines with its extraordinary performance on the New York Stock Exchange. Priced initially at **$10 per share**, Newsmax saw its stock—traded under the ticker symbol NMAX—skyrocket to close…

Gold Prices Skyrocket Amid Trump’s Tariff Revisions: Impact on Investors and Consumers

Gold Prices Surge as Trump’s Reciprocal Tariffs Reshape Import Landscape Gold prices have soared to unprecedented heights following President Donald Trump’s announcement of sweeping tariff revisions, marking a significant shift in America’s trade relationships and its impact on consumer costs. The precious metal climbed to a record $3,201.60 per ounce in aftermarket trading based on…

Larry Fink’s 2025 Letter: Emphasizing Private Capital and Pragmatism Over Politics

Larry Fink’s Annual Letter: A Shift Toward Pragmatism and Away from Political Discourse Each year, the financial world anticipates the release of Larry Fink’s letter, written by the CEO of BlackRock, the world’s largest asset manager, with $11.5 trillion in assets under management. This letter serves as a critical touchpoint for investors and analysts on…

How Trump’s Tariffs Might Derail Economic Stability: Lessons from Reagan’s Era

How Trump’s Tariffs Could Backfire: A Cautionary Tale from Reagan As the world watches the onset of President Trump’s second term, the economic policies reminiscent of his first administration come back into focus. Particularly, his stance on tariffs evokes Ronald Reagan’s warning that while tariffs “sometimes for a short while [work]—but only for a short…

Axsome’s Sunosi Trial Shows Mixed Results: Hope for Major Depressive Disorder Patients with Daytime Sleepiness

Axsome’s Sunosi Trial Yields Mixed Results, Showing Promise for MDD with Daytime Sleepiness In a recent announcement, Axsome Therapeutics revealed that its investigational drug, Sunosi (solriamfetol), has demonstrated mixed results in a phase 3 trial aimed at treating patients with major depressive disorder (MDD), particularly those experiencing excessive daytime sleepiness (EDS). A week after celebrating…

MicroStrategy’s First Bearish Analyst Recommendation: Should You Sell Your Shares?

MicroStrategy Faces First Bearish Analyst: Why Investors Should Consider Selling In a significant shift in sentiment on Wall Street, MicroStrategy Inc. (ticker: MSTR), now doing business as Strategy, has received its first bearish recommendation from analyst Gus Gala of Monness Crespi Hardt. This downgrade comes on the heels of the company’s recent aggressive moves to…

Trump’s TikTok Deadline: What Investors Need to Know to Cash In on the Drama

Trump to Review TikTok Deal as Deadline Looms Key Developments on the TikTok Scene President Trump is set to be briefed on a potential proposal aimed at keeping the wildly popular social media app TikTok operational within the United States, a move that comes as a deadline approaches for either selling or shutting down the…

Goldman’s Stagflation Warning: Revised S&P 500 Target and Escalating Recession Fears

Goldman’s Stagflationary Outlook: Revised S&P 500 Target and Rising Recession Risks As the April 2 tariff deadline approaches, financial markets are bracing for further uncertainty. In a recent note, analysts from Goldman Sachs have painted a grim picture for the S&P 500, cutting their short-term target amid growing concerns over stagflation. Market Context: Strain on…